Status:
COMPLETED
Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%
Lead Sponsor:
Universidad Nacional de Colombia
Conditions:
Chronic Blepharitis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Blepharitis is a endemic inflammatory disease caused mainly by Demodex folliculorum and Demodex Brevis, This mites are often associated with anaerobic bacteria that produces a skin inflammation, so a ...
Eligibility Criteria
Inclusion
- • Patients with symptomatic Demodex blepharitis for duration of at least 3 months.
- Age range: 18 yeras and older.
- Both genders and all ethnic groups comparable with the local community.
- Able to understand and willing to sign a written informed consent
- Able and willing to cooperate with the investigational plan.
- Able and willing to complete all mandatory follow-up visits.
Exclusion
- • Patients who are currently engaged in another clinical trial, unwilling or unable to give consent, to accept randomization, or to return for scheduled visits.
- Children under 18.
- Pregnant women or expecting to be pregnant during the study.
- Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant.
- Concomitant use of ophthalmic topical medications (excluding non-preserved tear substitutes).
- Concomitant use of systemic antibiotics or steroids.
- Contact lens wear
- Active ocular infection or allergy
- Unable to close eyes or uncontrolled blinking Previous allergic reaction to metronidazole and / or ivermectin
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02236403
Start Date
October 1 2014
End Date
January 1 2015
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Engativa
Bogotá, Colombia